Skip to main content

Table 1 Baseline characteristics

From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

Parameter

LX

TBP

P value

(N = 255)

(N = 299)

Age (year)

  < 50

137(53.7%)

161(53.8%)

0.977

  ≥ 50

59(23.1%)

95(31.8%)

0.024

 Unknown

59(23.1%)

43(14.4%)

0.008

Menopausal status

 Premenopausal

40(15.7%)

68(20.7%)

0.126

 Postmenopausal

182(71.4%)

204(68.2%)

0.422

 Unknown

33(12.9%)

27(9%)

0.14

HR Status

 Negative

136(53.3%)

145(48.5%)

0.256

 Positive

92(36.1%)

139(46.5%)

0.013

 Unknown

27(10.6%)

15(5%)

0.014

 Stage IV at initial diagnosis

32(12.5%)

55(18.4%)

0.059

Number of metastatic sites

  < 3

178(69.8%)

190(63.5%)

0.12

  ≥ 3

77(30.2%)

109(36.5%)

 

Metastases

 Lung

123(48.2%)

162(54.2%)

0.163

 Liver

109(42.7%)

143(47.8%)

0.213

 Bone

62(24.3%)

86(28.8%)

0.238

 Brain

24(9.4%)

34(11.4%)

0.453

 Other

131(51.4%)

150(50.2%)

0.78

Resistance

 Primary

96(37.6%)

109(38.1%)

0.772

 Secondary

159(62.4%)

190(61.9%)

 

Treatment line

 1

37(14.5%)

43(14.4%)

0.966

 2

94(36.9%)

164(54.8%)

<0.001

 3

124(48.6%)

92(30.8%)

0.001

Previous therapy

 Hormonal

  Adjuvant

76(29.8%)

96(32.1%)

0.559

  Metastatic

60(23.5%)

91(30.4%)

0.069

Radiotherapy

 Adjuvant

86(33.7%)

104(34.8%)

0.794

 Metastatic

44(17.3%)

54(18.1%)

0.804

Previous trastuzumab failure

 Adjuvant

37(14.5%)

43(14.4%)

0.966

 Metastatic

218(85.5%)

256(85.6%)

 

Previous trastuzumab treatment

 Adjuvant

78(30.6%)

67(22.4%)

0.029

 Advanced disease only

177(69.4%)

232(77.6%)

Â